Central Florida Treatment Center

What Central Florida Treatment Center does

Central Florida Treatment Center, operating legally as CFSATC Inc. and branded as Central Florida Treatment Centers, is a private for-profit outpatient addiction treatment provider founded in 1983 and headquartered in Orlando, FL. The company operates seven regulated Opioid Treatment Program (OTP) clinics across Central and South Florida — Orlando, Cocoa, Palm Bay, Titusville, Fort Pierce, Lake Worth, and Fort Lauderdale — delivering medication-assisted treatment (MAT) for opioid use disorder using methadone and buprenorphine (Suboxone) combined with individual and group counseling, urine toxicology monitoring, care coordination with primary care physicians, and alternative holistic adjuncts such as acupuncture, nutrition counseling, meditation, yoga, and pet therapy. The clinical model is supported by an experienced medical team under Medical Director Robert D. Lovinger, M.D. (author of a 2019 Elsevier addiction medicine primer) and holds The Joint Commission accreditation and HIPAA compliance.

The business operates a recurring, insurance-reimbursed healthcare revenue model, billing Medicare (Original and Advantage including Humana, United Health Care, WellCare, CarePlus, Avmed, Aetna, Simply, Freedom), Medicaid/TANF, the Veterans Affairs, and commercial plans such as Independence Blue FEP. Patient intake is driven by direct walk-ins to clinic sites, an online pre-screening form on methadoneworks.net, and referrals from healthcare providers, community resources, and the company's Narcan distribution partnership with the Florida Department of Children and Families. Go-to-market is sales-led and community-anchored rather than digitally scaled.

Strategic posture is steady organic expansion: a Titusville de novo opened June 21, 2022, complementing long-standing operations in the other six markets, with no reported M&A, outside capital, or technology platform acquisitions. The company remains privately held under independent ownership with no disclosed PE/VC backing, positioning it as a legacy regional operator rather than a venture-backed growth asset.

Name

Central Florida Treatment Center

Legal name

CFSATC Inc.

Website

https://methadoneworks.net

Company type

Private

Founded year

1983

Operating status

Operating

Headcount range

101–250 employees

Short description

Central Florida Treatment Center is a private Orlando-based outpatient addiction treatment provider operating seven medication-assisted treatment clinics across Florida, serving opioid use disorder patients with methadone and buprenorphine programs reimbursed by Medicare, Medicaid, VA, and commercial insurance.

Ownership category

akta.pro rank

Product category

Outpatient Opioid Addiction Treatment

NAICS

Outpatient Mental Health and Substance Abuse Centers (62142)

SIC

Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Medication-Assisted Treatment (MAT) & Opioid Treatment Programs (OTPs) (HLAFACAG)

akta.pro secondary industry

Outpatient Substance Use Treatment Programs (IOP/PHP/OP) (HLAFACAF)

Keywords

• Opioid addiction treatment
• Medication-assisted treatment
• Methadone maintenance therapy
• Outpatient addiction recovery
• Suboxone treatment services

Headquarters

HQ city

Orlando

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Healthcare Services - Opioid Treatment: Outpatient medication-assisted treatment services for opioid addiction including methadone dispensing, suboxone treatment, counseling, and clinical oversight. Revenue generated through insurance reimbursement, Medicaid, Medicare, and VA billing.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Central Florida Treatment Center operates an outpatient addiction recovery program specializing in medication-assisted treatment (MAT) for opioid and narcotic use disorders. The center dispenses methadone and buprenorphine (Suboxone) to manage withdrawal and cravings, combined with substance abuse counseling, urine toxicology monitoring, and individualized dose stabilization. Services are delivered through seven clinic locations across Central and South Florida and are billed through Medicare, Medicaid, VA, and commercial insurance plans.

Product overview

Central Florida Treatment Centers operates as a multi-location outpatient addiction and recovery treatment program specializing in medication-assisted treatment (MAT) for opioid use disorders. The core offering consists of methadone and buprenorphine (Suboxone) treatment programs, augmented with counseling therapy, alternative holistic approaches (acupuncture, nutrition, meditation, yoga, pet therapy), and diagnostic services including urine toxicology interpretation. The organization provides 6 clinic locations across Central and South Florida, with additional services including a pre-screening intake form, Narcan distribution program for community overdose prevention, and coordination of care with primary care physicians. The company has been operating since 1983 and is regulated by both Federal and State authority.

Differentiator

Problem solved

Functional benefit

Products and services

• Medication-Assisted Treatment (MAT) Program Comprehensive outpatient medication-assisted treatment program for opioid and narcotic use disorders, combining methadone or buprenorphine (Suboxone) dosing with substance abuse counseling, clinical oversight, and individualized recovery planning for adult patients.
• Methadone Maintenance Treatment Long-term methadone maintenance therapy for opioid use disorder, with individualized dose stabilization to the lowest effective therapeutic dose to minimize dependency while managing withdrawal and cravings.
• Suboxone/Buprenorphine Treatment Medication-assisted treatment using buprenorphine products (Suboxone, Subutex, Zubsolv) to manage opioid cravings and withdrawal symptoms for patients with opioid use disorder.
• Individual and Group Counseling Substance abuse therapy provided by experienced counselors addressing the psychological, emotional, and behavioral dimensions of opioid addiction recovery through individual and group sessions.
• Urine Toxicology Services Diagnostic urine toxicology testing combined with physician expertise in toxicology interpretation to monitor patient progress and inform treatment planning.

Quantifiable outcome

• Methadone treatment is considered the gold standard with the most satisfactory results in medical research for long-term opioid addiction treatment.

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and supporting.

• Florida Department of Children and FamiliescoreStrategic or Co-development Partner · 9 February 2021Partnership to provide Narcan, a life-saving medication used in opioid overdose cases, to community members. The program is part of a statewide initiative (isavefl.com) providing Narcan free or at low cost to community members in active addiction. The partnership aims to limit overdoses and help individuals find proper treatment for sobriety.
• SAMHSA (Substance Abuse and Mental Health Services Administration)supportingOthersFederal agency providing regulatory guidance and support for opioid treatment programs during COVID-19 pandemic, including letters to help free up personal protective equipment supplies.
• AATOD (American Association for the Treatment of Opioid Dependence)supportingOthersIndustry association providing policy guidance, advocacy, and COVID-19 response guidance for opioid treatment programs. AATOD President Mark W. Parrino contributed content to the company's COVID-19 response blog post.

Scale indicators2 records

Recent moves6 records

Expansion highlights2 records

Direct peers

• BayMark Health Services: BayMark is the largest US operator of opioid treatment programs, operating brands including MedMark and Aegis Treatment Centers with hundreds of clinics nationwide. Directly comparable to CFTC as an OTP/MAT provider using methadone and buprenorphine, with a similar regulatory and payer-driven model but at vastly greater scale and PE-backed growth.
• Operation PAR: Operation PAR is a Florida-based addiction treatment organization offering MAT, outpatient counseling, and community programs in the Tampa Bay region. Highly comparable to CFTC as a Florida-headquartered opioid treatment provider serving similar patient populations and payers.
• Behavioral Health Group: BHG operates a multi-state network of outpatient opioid treatment programs providing medication-assisted treatment, counseling, and recovery services. Comparable to CFTC in core service line (MAT/OTP), payer mix (Medicaid and commercial), and clinic-based delivery model.
• Aegis Treatment Centers: Aegis operates a network of outpatient opioid treatment programs providing methadone maintenance and buprenorphine services in California and beyond. Directly comparable to CFTC in modality (MAT/OTP), regulatory licensing, and patient population.
• Center for Behavioral Health: Center for Behavioral Health operates outpatient MAT clinics providing methadone and buprenorphine treatment with counseling across multiple states. Directly comparable to CFTC as an OTP delivering medication-assisted treatment to opioid-dependent patients through a clinic-based, insurance-reimbursed model.
• Crossroads Treatment Centers: Crossroads operates outpatient MAT clinics across the southeastern US, providing methadone and buprenorphine treatment for opioid use disorder. Direct competitor to CFTC in modality, regulatory class, and target patient population, with overlapping footprint in Florida and surrounding states.
• MedMark Treatment Centers: MedMark is a BayMark-owned brand operating outpatient methadone and buprenorphine treatment clinics across multiple US states. Directly comparable to CFTC as an OTP delivering medication-assisted treatment under federal/state regulation with insurance-based payment.
• New Season (Colonial Management Group): New Season operates one of the largest networks of MAT clinics in the US, offering methadone and buprenorphine treatment with counseling and outpatient services. Directly comparable to CFTC in modality (methadone and Suboxone), regulatory licensing (OTP), and patient population (opioid use disorder).

Emerging players

• CleanSlate Outpatient Addiction Medicine: CleanSlate operates an office-based outpatient addiction medicine model focused on buprenorphine treatment with a multi-state footprint. Comparable to CFTC's Suboxone/buprenorphine service line but uses a leaner office-based delivery model without methadone dispensing, representing a different cost structure competing for similar patients.

Broad incumbents

• Acadia Healthcare (CRC Health Group): Acadia Healthcare is a large publicly traded behavioral health provider operating inpatient psychiatric and addiction facilities nationwide, including the legacy CRC Health Group OTP assets. Broadly comparable to CFTC in addiction treatment delivery, but operates at vastly greater scale and across a wider service mix (inpatient, residential, outpatient).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/methadoneworks
• Facebookfacebook.com/281029161994865

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Central Florida Treatment Center